Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (22646)	6/24/1998 1:07:00 PM
From: jayhawk969	Read Replies (1) \| Respond to of 32384

And it further states "New treatment modalities using retinoid analogs to alter the downstream expression of the dopamine receptors and other genes that are targets of retinoid regulation, and that are thought to be involved in schizophrenia, are suggested". .

To: Pseudo Biologist who wrote (22646)	6/25/1998 12:06:00 PM
From: rocket	Respond to of 32384

Here's a short primer on schizophrenia: It is well known that excessive dopamine production causes hallucinations, often the prime symptom of schizophrenia. Current antipsychotic medications alll function as dopamine blockers or deleters, hopefully with the effect of decreasing or eliminating hallucinatory experiences. The main problem with current antipsychotics is their side effects, primarily as it relates to involuntary movements ( Parkinsonism, dystonias and dyskinesias). When dopamine blockade is undertaken, it upsets the crucial balance betwenn dopamine and other neurotransmitters, causing the involuntary movements. If retinoids can effectively treat dopamine (over)production before it reaches the synapse, LGND would have a huge winner as schizophrenia has a worldwide prevalence of 1 % of the population. Karl